Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$10.24
-1.2%
$8.01
$3.91
$13.99
$708.07M1.67812,684 shs310,023 shs
Quanterix Corporation stock logo
QTRX
Quanterix
$6.01
+2.0%
$5.72
$4.05
$16.74
$300.20M1.13791,352 shs284,025 shs
SiBone stock logo
SIBN
SiBone
$17.45
+1.5%
$18.23
$11.70
$20.05
$742.87M0.93392,032 shs95,418 shs
Transcat, Inc. stock logo
TRNS
Transcat
$86.62
+0.0%
$83.67
$67.56
$147.12
$807.11M0.7391,804 shs83,336 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+5.35%+14.73%+81.44%+0.29%
Quanterix Corporation stock logo
QTRX
Quanterix
0.00%-14.33%-2.81%+5.18%-59.35%
SiBone stock logo
SIBN
SiBone
0.00%-6.83%-1.26%+28.74%+12.27%
Transcat, Inc. stock logo
TRNS
Transcat
0.00%-3.66%+9.39%+4.00%-33.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
1.6027 of 5 stars
3.51.00.00.02.01.70.0
Quanterix Corporation stock logo
QTRX
Quanterix
2.5813 of 5 stars
3.21.00.00.03.33.30.6
SiBone stock logo
SIBN
SiBone
3.987 of 5 stars
3.52.00.03.32.02.50.6
Transcat, Inc. stock logo
TRNS
Transcat
2.9387 of 5 stars
3.33.00.00.02.51.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$25.67150.70% Upside
Quanterix Corporation stock logo
QTRX
Quanterix
2.40
Hold$13.50124.63% Upside
SiBone stock logo
SIBN
SiBone
3.00
Buy$22.5028.93% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.60
Moderate Buy$112.2029.54% Upside

Current Analyst Ratings Breakdown

Latest QTRX, SIBN, TRNS, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Transcat, Inc. stock logo
TRNS
Transcat
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$105.00
6/25/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$116.00
6/17/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$28.00
5/29/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/21/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00 ➝ $116.00
5/16/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/13/2025
Quanterix Corporation stock logo
QTRX
Quanterix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/8/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$56.04M12.57N/AN/A$4.93 per share2.08
Quanterix Corporation stock logo
QTRX
Quanterix
$137.42M2.18N/AN/A$8.57 per share0.70
SiBone stock logo
SIBN
SiBone
$167.18M4.45N/AN/A$3.98 per share4.38
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M2.90$4.27 per share20.29$30.82 per share2.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)
Quanterix Corporation stock logo
QTRX
Quanterix
-$38.53M-$1.30N/AN/AN/A-36.82%-15.07%-12.26%8/6/2025 (Estimated)
SiBone stock logo
SIBN
SiBone
-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$14.52M$1.5655.5132.93N/A5.21%6.47%5.02%8/4/2025 (Estimated)

Latest QTRX, SIBN, TRNS, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.67N/AN/AN/A$6.82 millionN/A
8/4/2025Q2 2025
SiBone stock logo
SIBN
SiBone
-$0.19N/AN/AN/A$48.12 millionN/A
8/4/2025Q1 2026
Transcat, Inc. stock logo
TRNS
Transcat
$0.41N/AN/AN/AN/AN/A
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66$0.64-$0.02$0.48$76.40 million$77.13 million
5/12/2025Q1 2025
Quanterix Corporation stock logo
QTRX
Quanterix
-$0.69-$0.53+$0.16-$0.53$28.27 million$30.33 million
5/7/2025Q1 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
5/5/2025Q1 2025
SiBone stock logo
SIBN
SiBone
-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Quanterix Corporation stock logo
QTRX
Quanterix
N/AN/AN/AN/AN/A
SiBone stock logo
SIBN
SiBone
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
7.85
7.79
Quanterix Corporation stock logo
QTRX
Quanterix
N/A
8.29
7.53
SiBone stock logo
SIBN
SiBone
0.21
8.53
7.26
Transcat, Inc. stock logo
TRNS
Transcat
0.11
2.29
1.87

Institutional Ownership

CompanyInstitutional Ownership
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Quanterix Corporation stock logo
QTRX
Quanterix
86.48%
SiBone stock logo
SIBN
SiBone
98.11%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%

Insider Ownership

CompanyInsider Ownership
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
Quanterix Corporation stock logo
QTRX
Quanterix
6.90%
SiBone stock logo
SIBN
SiBone
3.90%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.81 million65.74 millionOptionable
Quanterix Corporation stock logo
QTRX
Quanterix
46049.95 million46.51 millionOptionable
SiBone stock logo
SIBN
SiBone
35042.62 million40.95 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
1,2459.32 million9.10 millionOptionable

Recent News About These Companies

Transcat: Struggling Here

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$10.24 -0.12 (-1.18%)
As of 02:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Quanterix stock logo

Quanterix NASDAQ:QTRX

$6.01 +0.12 (+2.04%)
As of 02:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

SiBone stock logo

SiBone NASDAQ:SIBN

$17.45 +0.25 (+1.47%)
As of 02:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Transcat stock logo

Transcat NASDAQ:TRNS

$86.62 +0.03 (+0.03%)
As of 02:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.